Apogee Therapeutics (NASDAQ:APGE) Chief Financial Officer Henderson Jane reported the sale of 2,000 shares of common stock on April 1, 2026, bringing total proceeds from the transactions to approximately $170,020.
The disposition was executed in two separate tranches. The first tranche saw 900 shares sold at a weighted average price of $84.46, with individual sale prices ranging from $84.15 to $85.05. The second tranche comprised 1,100 shares sold at a weighted average price of $85.46, with trade prices between $85.17 and $85.79.
The timing of Jane's sales coincided with Apogee's shares trading near their 52-week high of $85.94, following a one-year price appreciation of about 161%. An InvestingPro analysis cited in company-related disclosures indicates the stock currently appears overvalued relative to its Fair Value; the platform also notes additional valuation metrics and 14 supplementary ProTips for APGE.
Following the reported transactions, Henderson Jane directly holds 177,371 shares of Apogee Therapeutics. The sales were carried out pursuant to a Rule 10b5-1 trading plan the CFO adopted on September 2, 2025.
Separately, Apogee has been active on the capital markets and with clinical communications. The company completed an underwritten public offering of 5.75 million common shares priced at $70.00 per share, which raised roughly $403 million in gross proceeds. That offering reflected the full exercise by underwriters of their option to purchase an additional 750,000 shares. After estimated expenses, net proceeds from the offering are expected to be in the vicinity of $377.4 million.
Analysts have reacted to recent clinical updates and corporate activity. Mizuho raised its price target for Apogee to $110 from $105 while maintaining an Outperform rating; the firm cited a presentation of 52-week data for zumilokibart in atopic dermatitis and said that information increased Mizuho's assessed probability of success for the treatment by 10 percentage points. BTIG reiterated its Buy rating with a $137 price target, calling attention to the company's recent data presentation at the American Academy of Dermatology (AAD), which included favorable results and supplementary analyses.
These financial and clinical developments have coincided with an elevated share price and increased analyst attention. The reported insider sale, the completed public offering and the analyst commentary together provide investors with updated information on Apogee's capital base, insider holdings and the market's reception to recent clinical communications.